SandlerResearch

Asthma - Drug Pipeline Analysis and Market Forecasts to 2016 Now Available at SandlerResearch

 

Dallas, TX -- (SBWIRE) -- 11/22/2010 -- SandlerResearch announce it will carry Asthma - Drug Pipeline Analysis and Market Forecasts to 2016 Market Research Report in its Store.

GlobalData, the industry analysis specialist, has released its new report, “Asthma - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Asthma market. The report identifies the key trends shaping and driving the global Asthma market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Hepatitis B sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the global asthma market to be valued at $12.4 billion in 2009. It is expected to grow with a Compound Annual Growth Rate (CAGR) of approximately 1.5% from $12.4 billion in 2009 to $14 billion by 2017. Although the respiratory market has expanded considerably from 2004 to 2009, growth in the seven major markets is expected to slow down from 2010 to 2012.The decline is sales during this period would be due to patent expiries of leading brands. Growth is driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages like route of administration, once-daily administration, combinational therapies etc.

Scope

The scope of the report includes:
• Annualized global Asthma market revenue data from 2001 to 2009, forecast for eight years to 2017.

• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.

• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Beta-2 Adrenoceptor Agonist, Immunotherapy, Interleukin inhibitors, Phosphodiesterase 4 (PDE4) Inhibitors, CRTh2 antagonists, Peroxisome Proliferator Activator Receptor (PPAR) agonist, Glucocorticoid receptor agonist and Prostaglandin D2 (PGD2) Receptor Antagonist.

• Analysis of the current and future market competition in the global Asthma market. The key future market players covered are GlaxoSmithKline Inc., AstraZeneca PLC, Pfizer Inc., Merck & Co., Inc., Skye Pharma PLC, Schering-Plough, PARI Pharma, Glenmark Pharmaceuticals Limited, Theravance Inc., Aerovance and Boehringer Ingelheim GmbH.

• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

• Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the Asthma market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

• Develop business strategies by understanding the trends shaping and driving the global Asthma therapeutics market.

• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global Asthma market in the future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

• What’s the next big thing in the global Asthma market landscape? Identify, understand and capitalize.
Browse complete Report on: Asthma - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.sandlerresearch.org/reports/15806-asthma-drug-pipeline-analysis-and-market-forecasts-to-2016.html
1 Table of contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Global Asthma Market: Introduction 6
2.1 GlobalData Pipeline Report Guidance 6

3 Global Asthma Market: Market Characterization 7
3.1 Overview 7
3.2 Asthma Market Size 7
3.3 Asthma Market Forecast and CAGR 7
3.4 Drivers and Barriers for Asthma Market 9
3.4.1 Drivers for Asthma Market 9
3.4.2 Barriers for Asthma Market 9
3.5 Opportunity and Unmet Need 10
3.6 Key Takeaway 11

4 Asthma Market: Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in Asthma Market 13
4.3.1 Singulair (montekeulast sodium) 13
4.3.2 Accolate (zafirlukast, Accoleit, Vanticon) 15
4.3.3 Zyflo (zileuton) 16
4.3.4 Foradil (formoterol fumarate inhalation powder) 17
4.3.5 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) 18
4.3.6 Xolair (omalizumab) 19
4.3.7 Serevent Diskus (salmaterol xinafoate inhalation powder) 21
4.3.8 Advair Diskus (fluticasone propionate and salmeterol inhalation powder) 22
4.4 Key Takeaway 27

5 Asthma Market: Pipeline Assessment 28
5.1 Overview 28
5.2 Strategic Pipeline Assessment 28
5.2.1 Technology Trends Analytic Framework 28
5.3 Asthma Therapeutics – Promising Drugs under Clinical Development 30
5.4 Molecule Profile for Promising Drug for Asthma under Clinical Development 31
5.4.1 Daxas (Roflumilast) (Daxas, APTA 2217, B9302-107, BY 217, BYK 20869) 31
5.5 Asthma Therapeutics Market – Clinical Pipeline by Mechanism of Action 33
5.6 Asthma Pipeline – Pipeline by Clinical Phases of Development 34
5.6.1 Asthma Therapeutics – Phase III Clinical Pipeline 34
5.6.2 Asthma Therapeutics – Phase II Clinical Pipeline 36
5.6.3 Asthma Therapeutics – Phase I Clinical Pipeline 39
5.6.4 Asthma Therapeutics – Pre-clinical Pipeline 41
5.6.5 Asthma Therapeutics – Discovery Pipeline 42
5.7 Key Takeaway 42

6 Asthma Market – Implications for Future Market Competition 43

7 Asthma Market – Future Players in the Asthma Market 45
7.1 Introduction 45
7.1.1 SkyePharma PLC. 45
7.1.2 Respiratory Disease Portfolio 46
7.1.3 Asthma Product Portfolio 46
7.2 Merck & Co., Inc. 48
7.2.1 Overview 48
7.2.2 Respiratory Disease Portfolio 49
7.2.3 Asthma Product Portfolio 49
7.3 Nycomed 49
7.3.1 Overview 49
7.3.2 Respiratory Disease Portfolio 49
7.3.3 Asthma Product Portfolio 50
7.4 GlaxoSmithKline plc. 51
7.4.1 Overview 51
7.4.2 Respiratory Disease Portfolio 52
7.4.3 Asthma Product Portfolio 53
7.5 Glenmark 55
7.5.1 Overview 55
7.5.2 Respiratory Disease Portfolio 55
7.5.3 Asthma Product Portfolio 56
7.6 Aerovance Inc. 56
7.6.1 Overview 56
7.6.2 Respiratory Disease Portfolio 57
7.6.3 Asthma Product Portfolio 57
7.7 Theravance, Inc. 58
7.7.1 Overview 58
7.7.2 Respiratory Disease Portfolio 58
7.7.3 Asthma Product Portfolio 58

8 Asthma Market: Appendix 60
8.1 Market Definitions 60
8.2 Scope of Pipeline Research 60
8.3 Abbreviations 60
8.4 Research Methodology 61
8.4.1 Coverage 61
8.4.2 Secondary Research 62
8.4.3 Forecasting 62
8.4.4 Primary Research 65
8.4.5 Expert Panel validation 65
8.5 Contact Us 65
8.6 Disclaimer 65
8.7 Sources 66

1.1 List of Tables

Table 1: Asthma Therapeutics, Global, Revenue ($bn), 2001-2009 8
Table 2: Asthma Therapeutics, Global, Market Forecasts ($bn), 2009-2017 8
Table 3: Major Marketed Products Comparison in the Asthma Market, 2010 25
Table 4: Asthma Therapeutics – Most Promising Drugs Under Clinical Development, 201 30
Table 5: Asthma Therapeutics – Phase III Clinical Pipeline, 2010 34
Table 6: Asthma Therapeutics – Phase II Clinical Pipeline, 2010 36
Table 7: Asthma Therapeutics – Phase I Clinical Pipeline, 2010 39
Table 8: Asthma Therapeutics – Pre-clinical Pipeline, 2010 41
Table 9: Asthma Therapeutics – Discovery Pipeline, 2010 42
Table 11: Skye Pharma–Respiratory Pipeline Products, 2010 46
Table 12: Merck & Co., Inc. – Respiratory Pipeline Products, 2010 49
Table 13: Nycomed – Respiratory Disease Pipeline Products, 2010 49
Table 14: GlaxoSmithKline plc – Respiratory Disease Pipeline Products, 2010 52
Table 15: Glenmark Pharmaceuticals Limited- Respiratory Disease Pipeline Products, 2010 55
Table 17: Aerovance Inc. – Respiratory Disease Pipeline Products, 2010 57
Table 18: Theravance, Inc. – Respiratory Disease Pipeline Products, 2010 58

1.2 List of Figures

Figure 1: Asthma Therapeutics, Global, Revenue ($bn), 2001–2009 7
Figure 2: Asthma Therapeutics, Global, Market Forecast ($bn), 2009-2017 8
Figure 3: Opportunity and Unmet Need in the Asthma Therapeutics Market 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Asthma, 2010 13
Figure 5: Technology Trends Analytic Framework of the Asthma Pipeline, 2010 29
Figure 6: Technology Trends Analytic Framework of the Asthma Pipeline – Description, 2010 30
Figure 7: Asthma Therapeutics – Clinical Pipeline by Mechanism of Action, 2010 33
Figure 8: Asthma Therapeutics - Pipeline by Phase of Clinical Development, 2010 34
Figure 9: Implications for Future Market Competition in the Asthma Therapeutics Market, 2010 43
Figure 10: Asthma Therapeutics Market – Clinical Pipeline by Company, Number of Molecules, 2010 45
Figure 11: GlobalData Market Forecasting Model 64
Browse all Pharmaceuticals Market Research Reports on:
http://www.sandlerresearch.org/market-research/pharmaceuticals/

Browse all GlobalData Market Research Reports on:
http://www.sandlerresearch.org/publishers/globaldata/

Browse all Newly Published Market Research Reports on:
http://www.sandlerresearch.org/LatestReport.aspx

Related Reports:
Head and Neck Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.sandlerresearch.org/reports/15789-head-and-neck-cancer-drug-pipeline-analysis-and-market-forecast.html

Amyotrophic Lateral Sclerosis (Lou Gehrig's) - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.sandlerresearch.org/reports/16232-amyotrophic-lateral-sclerosis-lou-gehrigs-drug-pipeline-anal.html

Erectile Dysfunction - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.sandlerresearch.org/reports/23284-erectile-dysfunction-drug-pipeline-analysis-and-market-forecast.html
Tuberculosis - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.sandlerresearch.org/reports/23285-tuberculosis-drug-pipeline-analysis-and-market-forecasts-to-201.html

Hepatitis B - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.sandlerresearch.org/reports/23286-hepatitis-b-drug-pipeline-analysis-and-market-forecasts-to-2016.html

About Sandler Research
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.

Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques, in order to generate better revenues for our clients, entailing positive and robust results.

We also provide 24/7 online and offline support to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.sandlerresearch.com